Annual rank23
Sweden · Healthcare
Camurus
Camurus develops and commercialises long-acting medicines for treating severe and chronic diseases.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Long-acting medicines built from a self-forming injection depot
Camurus is a Lund-based biopharmaceutical company built around FluidCrystal, a lipid formulation that changes structure after injection and releases a medicine over days, weeks or months. The platform underpins marketed treatments for opioid dependence and acromegaly, a clinical pipeline in endocrine, metabolic and oncology-related conditions, and partnerships that pair Camurus' delivery technology with other companies' active compounds.
Drug-delivery technology
A liquid injection assembles its own medicine depot
FluidCrystal combines endogenous polar lipids with an active substance. After subcutaneous injection, contact with tissue fluid turns the liquid into a crystalline gel; the matrix then degrades gradually and releases the medicine. Camurus tunes the composition for delivery periods ranging from days to months.
- How FluidCrystal works The lipid matrix, injection process and controllable release profile
- ▶ VideoWatch: the depot forms Camurus' English animation of injection, gel formation and release
- Business model In-house development, direct commercialisation and partnerships
Medicines and markets
One formulation platform, three commercial names
Buvidal provides weekly or monthly buprenorphine injections for opioid dependence in multiple markets. The same product is sold in the US as Brixadi by licensee Braeburn. Oczyesa is the authorised EU/UK brand for Camurus' monthly octreotide depot in acromegaly; Oclaiz is the proposed US brand for CAM2029 and remains under FDA review. Both use a prefilled autoinjector designed for self-administration.
- Product portfolio Buvidal, Brixadi and Oczyesa, with administration formats
- Brixadi in the US The Braeburn licence and weekly or monthly product launch
- Oclaiz US review Proposed US brand, accepted review and 18 December target date
- Oczyesa authorisation The once-monthly autoinjector and EU treatment setting
- Buvidal market expansion An example of direct European commercialisation in Portugal
Pipeline and partnering
Extend the depot across molecules and disease areas
The pipeline applies long-acting depots to octreotide, semaglutide, setmelanotide, treprostinil and other active substances. Programmes span neuroendocrine tumours, polycystic liver disease, chronic pain, rare genetic obesity and metabolic disease. Partnerships extend the platform further: the Lilly collaboration covers long-acting incretin programmes and expanded in Q2 when Lilly exercised its amylin option, while Camurus and Gubra selected a lead long-acting PTH analogue for hypoparathyroidism.
- R&D pipeline Named candidates, development stages and target conditions
- Lilly collaboration Long-acting FluidCrystal incretins using selected Lilly compounds
- Q2 partnership progress Gubra lead candidate, Lilly amylin and CAM2056 status
- Monthly semaglutide programme CAM2056 and the planned transition beyond Phase 1b
- CAM2029 regulatory pathway The US review and the broader octreotide development programme
Why dosing routines matter
Stories make chronic treatment burden visible
Camurus' English story library puts the science beside lived experience. Mattias describes opioid dependence that began with prescribed pain relief; Ken recounts an acromegaly diagnosis reached after years of symptoms; Dusty describes learning that an apparent terminal cancer diagnosis was a neuroendocrine tumour she could live with.
- Disease areas Opioid dependence, rare diseases and oncology-related conditions
- Mattias' story When prescribed pain relief developed into opioid dependence
- Ken's story A long path from unexplained symptoms to acromegaly diagnosis
- Dusty's story Living with a gastroenteropancreatic neuroendocrine tumour
Official profile sources: About us — Camurus · FluidCrystal technology
Current 2026 update
What is changing at Camurus in 2026?
Camurus is turning FluidCrystal into three businesses: wider opioid-dependence access, a second commercial franchise around monthly octreotide and partner-funded programmes beyond its established disease areas.
The change in one sentence
One depot technology is moving across medicines, markets and partnerships.
The 2026 tests are patient access for Buvidal/Brixadi, Oczyesa/Oclaiz execution across regulatory systems, and whether Lilly, Gubra and CAM2056 broaden the pipeline.
Four lenses on 2026
The same four-quadrant format used in the Company profile.
01 · Opioid treatment access
Buvidal and Brixadi widen access through different commercial models
Camurus sells weekly or monthly Buvidal directly across Europe, Australia and MENA, while Braeburn markets the same medicine as Brixadi in the US. Camurus estimated 77,000 Buvidal patients at Q2; Braeburn expanded its US commercial and medical-affairs teams. NSW Health says Australian Sublocade supply ends on 31 December, but that does not guarantee transfers to Buvidal.
- Current signal77,000 estimated Buvidal patients · Brixadi US expansion
- Why it mattersOne medicine depends on direct selling, licensing and health-system access across distinct markets.
- Q2 products and markets Patient estimate, commercial models and US team expansion
- Australian withdrawal notice Sublocade timing and the current long-acting options
02 · A second franchise
Oczyesa is launching while Oclaiz remains under FDA review
Oczyesa, the EU/UK brand, continued its German launch, reached first patients in Sweden and awaited UK formulary outcomes. Oclaiz is the proposed US brand for CAM2029: FDA review runs to 18 December after a third-party manufacturing inspection, with no efficacy or safety concern cited in the response letter. In GEP-NET, SORENTO's target event count is expected in Q4, followed by readout.
- Current signalEU/UK authorised · US target date 18 December
- Why it mattersThe same depot must prove commercial uptake, regulatory execution and clinical expansion across three diseases.
- Q2 products and pipeline European rollout and SORENTO timing
- Oclaiz US review Resubmission, manufacturing boundary and target date
03 · Platform partnerships
Lilly and Gubra add programmes beyond the current franchises
Lilly exercised its amylin option, extending work across dual GIP/GLP-1, triple GIP/glucagon/GLP-1 and amylin programmes. Camurus and Gubra selected a lead long-acting PTH analogue for further development in hypoparathyroidism. Separately, Camurus planned a second-half Phase 2b start for monthly semaglutide CAM2056; none of these milestones establishes a marketed product.
- Current signalLilly adds amylin · Gubra lead selected
- Why it mattersThe programmes test whether Camurus can extend long-acting delivery into metabolic and rare endocrine categories.
- Lilly collaboration Amylin option and covered incretin programmes
- Q2 R&D progress Gubra lead selection and CAM2056 preparation
04 · What to watch
Three questions that test the FluidCrystal expansion
Later disclosures must separate access, regulatory milestones and early development progress.
- Patient accessDo UK funding, Australian continuity work and Braeburn's larger US team broaden treatment access?
- CAM2029 franchiseDoes Oczyesa uptake broaden, does Oclaiz clear the 18 December FDA review and does SORENTO reach its event target and report results?
- Platform deliveryDoes CAM2056 start Phase 2b, and what milestones follow for the Lilly and Gubra programmes?
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 23 | +144% | +1265% | +144% |